SEARCH

SEARCH BY CITATION

References

  • 1
    Mansfield SG, Kole J, Puttaraju M, Yang CC, Garcia-Blanco MA, Cohn JA & Mitchell LG (2000) Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. Gene Ther 7, 18851895.
  • 2
    Emery AE (2002) The muscular dystrophies. Lancet 359, 687695.
  • 3
    Bashir A, Liu YT, Raphael BJ, Carson D & Bafna V (2007) Optimization of primer design for the detection of variable genomic lesions in cancer. Bioinformatics 23, 28072815.
  • 4
    Liu X, Jiang Q, Mansfield SG, Puttaraju M, Zhang Y, Zhou W, Cohn JA, Garcia-Blanco MA, Mitchell LG & Engelhardt JF (2002) Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol 20, 4752.
  • 5
    Nguyen K, Bassez G, Krahn M, Bernard R, Laforet P, Labelle V, Urtizberea JA, Figarella-Branger D, Romero N, Attarian S et al. (2007) Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 64, 11761182.
  • 6
    Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, Walsh J, Johnson MA, Bashir R, Britton S, Keers S et al. (1999) Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 8, 855861.
  • 7
    Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, McNeil PL & Campbell KP (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423, 168172.
  • 8
    de Luna N, Gallardo E, Soriano M, Dominguez-Perles R, de la Torre C, Rojas-Garcia R, Garcia-Verdugo JM & Illa I (2006) Absence of dysferlin alters myogenin expression and delays human muscle differentiation ‘in vitro. J Biol Chem 281, 1709217098.
  • 9
    Roche JA, Lovering RM & Bloch RJ (2008) Impaired recovery of dysferlin-null skeletal muscle after contraction-induced injury in vivo. NeuroReport 19, 15791584.
  • 10
    Krahn M, Borges A, Navarro C, Schuit R, Stojkovic T, Torrente Y, Wein N, Pecheux C & Levy N (2009) Identification of different genomic deletions and one duplication in the dysferlin gene using multiplex ligation-dependent probe amplification and genomic quantitative PCR. Genet Test Mol Biomarkers 13, 439442.
  • 11
    Takahashi T, Aoki M, Tateyama M, Kondo E, Mizuno T, Onodera Y, Takano R, Kawai H, Kamakura K, Mochizuki H et al. (2003) Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. Neurology 60, 17991804.
  • 12
    Lu QL, Morris GE, Wilton SD, Ly T, Artem'yeva OV, Strong P & Partridge TA (2000) Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol 148, 985996.
  • 13
    Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ & van Deutekom JC (2002) Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 12 (Suppl 1), S7177.
  • 14
    Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L & Danos O (2004) Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306, 17961799.
  • 15
    Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC & Aartsma-Rus A (2009) In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11, 257266.
  • 16
    Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT & van Deutekom JC (2004) Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 74, 8392.
  • 17
    Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G & Partridge T (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102, 198203.
  • 18
    Krahn M, Beroud C, Labelle V, Nguyen K, Bernard R, Bassez G, Figarella-Branger D, Fernandez C, Bouvenot J, Richard I et al. (2009) Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 30, E345375.
  • 19
    Sinnreich M, Therrien C & Karpati G (2006) Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology 66, 11141116.
  • 20
    Wein N, Avril A, Bartoli M, Beley C, Chaouch S, Laforet P, Behin A, Butler-Browne G, Mouly V, Krahn M et al. (2010) Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat 31, 136142.
  • 21
    Gao G, Vandenberghe LH & Wilson JM (2005) New recombinant serotypes of AAV vectors. Curr Gene Ther 5, 285297.
  • 22
    Hermonat PL, Quirk JG, Bishop BM & Han L (1997) The packaging capacity of adeno-associated virus (AAV) and the potential for wild-type-plus AAV gene therapy vectors. FEBS Lett 407, 7884.
  • 23
    Duan D, Yue Y, Yan Z & Engelhardt JF (2000) A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med 6, 595598.
  • 24
    Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, Harper HA, Robinson AS, Engelhardt JF, Brooks SV et al. (2002) Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 8, 253261.
  • 25
    Krahn M, Wein N, Bartoli M, Lostal W, Courrier S, Bourg-Alibert N, Nguyen K, Vial C, Streichenberger N, Labelle V et al. (2010) A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci Transl Med 2, 50ra69.
  • 26
    Lostal W, Bartoli M, Bourg N, Roudaut C, Bentaib A, Miyake K, Guerchet N, Fougerousse F, McNeil P & Richard I (2010) Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 19, 18971907.
  • 27
    Grose WE, Clark KR, Griffin D, Malik V, Shontz KM, Montgomery CL, Lewis S, Brown RH Jr, Janssen PM, Mendell JR et al. (2012) Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One 7, e39233.
  • 28
    Endo T (2007) Stem cells and plasticity of skeletal muscle cell differentiation: potential application to cell therapy for degenerative muscular diseases. Regen Med 2, 243256.
  • 29
    Nowak KJ & Davies KE (2004) Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 5, 872876.
  • 30
    Singh N, Pillay V & Choonara YE (2007) Advances in the treatment of Parkinson's disease. Prog Neurobiol 81, 2944.
  • 31
    Torrente Y, Belicchi M, Sampaolesi M, Pisati F, Meregalli M, D'Antona G, Tonlorenzi R, Porretti L, Gavina M, Mamchaoui K et al. (2004) Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest 114, 182195.
  • 32
    Benchaouir R, Meregalli M, Farini A, D'Antona G, Belicchi M, Goyenvalle A, Battistelli M, Bresolin N, Bottinelli R, Garcia L et al. (2007) Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell 1, 646657.
  • 33
    Farini A, Sitzia C, Navarro C, D'Antona G, Belicchi M, Parolini D, Del Fraro G, Razini P, Bottinelli R, Meregalli M et al. (2012) Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model. Exp Cell Res 318, 11601174.
  • 34
    Cartegni L & Krainer AR (2003) Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 10, 120125.
  • 35
    Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M & Beroud C (2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37, e67.
  • 36
    Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ & van Deutekom JC (2004) Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther 11, 13911398.
  • 37
    Ittig D, Liu S, Renneberg D, Schumperli D & Leumann CJ (2004) Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA. Nucleic Acids Res 32, 346353.
  • 38
    Follenzi A, Ailles LE, Bakovic S, Geuna M & Naldini L (2000) Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25, 217222.
  • 39
    Mortellaro A, Hernandez RJ, Guerrini MM, Carlucci F, Tabucchi A, Ponzoni M, Sanvito F, Doglioni C, Di Serio C, Biasco L et al. (2006) Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood 108, 29792988.
  • 40
    Li S, Kimura E, Fall BM, Reyes M, Angello JC, Welikson R, Hauschka SD & Chamberlain JS (2005) Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Ther 12, 10991108.
  • 41
    Quenneville SP, Chapdelaine P, Skuk D, Paradis M, Goulet M, Rousseau J, Xiao X, Garcia L & Tremblay JP (2007) Autologous transplantation of muscle precursor cells modified with a lentivirus for muscular dystrophy: human cells and primate models. Mol Ther 15, 431438.
  • 42
    Ho M, Post CM, Donahue LR, Lidov HG, Bronson RT, Goolsby H, Watkins SC, Cox GA & Brown RH Jr (2004) Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 13, 19992010.
  • 43
    Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, Lako M, Richard I, Marchand S, Bourg N, Argov Z et al. (1998) A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 20, 3742.
  • 44
    Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB et al. (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20, 3136.
  • 45
    Surono A, Van Khanh T, Takeshima Y, Wada H, Yagi M, Takagi M, Koizumi M & Matsuo M (2004) Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of Duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. Hum Gene Ther 15, 749757.
  • 46
    De Luna N, Freixas A, Gallano P, Caselles L, Rojas-Garcia R, Paradas C, Nogales G, Dominguez-Perles R, Gonzalez-Quereda L, Vilchez JJ et al. (2007) Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul Disord 17, 6976.
  • 47
    Therrien C, Dodig D, Karpati G & Sinnreich M (2006) Mutation impact on dysferlin inferred from database analysis and computer-based structural predictions. J Neurol Sci 250, 7178.
  • 48
    Millay DP, Maillet M, Roche JA, Sargent MA, McNally EM, Bloch RJ & Molkentin JD (2009) Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol 175, 18171823.
  • 49
    Lostal W, Bartoli M, Roudaut C, Bourg N, Krahn M, Pryadkina M, Borel P, Suel L, Roche JA, Stockholm D et al. (2012) Lack of correlation between outcomes of membrane repair assay and correction of dystrophic changes in experimental therapeutic strategy in dysferlinopathy. PLoS One 7, e38036.
  • 50
    Dellavalle A, Sampaolesi M, Tonlorenzi R, Tagliafico E, Sacchetti B, Perani L, Innocenzi A, Galvez BG, Messina G, Morosetti R et al. (2007) Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol 9, 255267.
  • 51
    Gavina M, Belicchi M & Camirand G (2006) VCAM-1 expression on dystrophic muscle vessels has a critical role in the recruitment of human blood-derived CD133+ stem cells after intra-arterial transplantation. Blood 108, 28572866.
  • 52
    Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D'Antona G, Pellegrino MA, Barresi R, Bresolin N, De Angelis MG, Campbell KP et al. (2003) Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301, 487492.
  • 53
    Gupta RC, Earley K & Sharma S (1988) Use of human peripheral blood lymphocytes to measure DNA binding capacity of chemical carcinogens. Proc Natl Acad Sci USA 85, 35133517.
  • 54
    Klinge L, Laval S, Keers S, Haldane F, Straub V, Barresi R & Bushby K (2007) From T-tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis. FASEB J 21, 17681776.
  • 55
    Summan M, Warren GL, Mercer RR, Chapman R, Hulderman T, Van Rooijen N & Simeonova PP (2006) Macrophages and skeletal muscle regeneration: a clodronate-containing liposome depletion study. Am J Physiol Regul Integr Comp Physiol 290, R1488R1495.
  • 56
    Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D & Naldini L (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72, 84638471.
  • 57
    Zufferey R, Nagy D, Mandel RJ, Naldini L & Trono D (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15, 871875.
  • 58
    Charrier S, Stockholm D, Seye K, Opolon P, Taveau M, Gross DA, Bucher-Laurent S, Delenda C, Vainchenker W, Danos O et al. (2005) A lentiviral vector encoding the human Wiskott–Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther 12, 597606.
  • 59
    Diaz-Manera J, Touvier T, Dellavalle A, Tonlorenzi R, Tedesco FS, Messina G, Meregalli M, Navarro C, Perani L, Bonfanti C et al. (2010) Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy. Cell Death Dis 1, e61.